Scientific Online Resource System

Varna Medical Forum

Prognostic significance of Epidermal Growth factor receptor in colon cancer patients on surgical treatment

Emil Kanchev, Georgi Kobakov, Kiril Kirov, Daniel Yankov, Petya Koleva, Snezhana Vicheva, Daniel Kostov, Nikolay Georgiev, Zdravko Dimitrov, Yordan Borisov

Abstract

Recently, pathological expression of epidermal growth factor receptor (EGFR) is increasingly used in the diagnosis of various epidermal tumours. The aim of this study is to analyze the role of EGFR in comparison to p53 as a prognostic marker in patients with colon cancer who undergo surgical treatment.

Two types of immunohistochemical examinations (for EGFR and p53) have been performed in 120 patients with colon cancer histologically verified by using of hematoxylin-eosin staining.

Our results clearly demonstrate that EGFR expression is present in 18 patients (in 15% of the cases). It occurs much more often in the patient with TNM stage II and especially in those with TNM stage III and relatively more frequently in the patients aged between 51 and 70 years and presenting with a moderately differentiated tumour. Besides, this expression immediately relates to a recurrence of the disease and worsened clinical course. There exists a correlation between the enhanced expression of EGFR and that of p53. Because of the small sample, our results are not statistically significant.

EGFR can serve as an independent prognostic factor and indicator of more common recurrences of the disease, worse quality of life and poorer prognosis in colon cancer patients. Further intensive collaboration between coloproctologists and pathologists is needed to improve the individualized surgical behaviour in such patients.


Keywords

oncogenic proteins; epidermal growth factor receptor. p53; colon cancer; prognosis

Full Text


References

Хаджиолов, Н. Д. Онкогенни протеини, клетъчна пролиферация и апоптоза в хода на туморогенезата. Дисертация за степен „доктор на медицинските науки”. София, 2006.

Хаджиолов, Н. Експресия на онкогенни протеини при преканцерози на дебелото черво и при колоректален карцином (КРК).- В: Онкологична хирургия - съвременен стандарт. Под ред. Д. Дамянов. София, Медарт, 2009, 240-246.

Cunningham, M. P., S. Essapen, H. Thomas, N. Green, D. P. Lovell, C. Topham, C. Marks, H. Modjtahedi. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.- Int. J. Oncol., 27, 2005, No 2, 317-325.

Cunningham, M. P., S. Essapen, H. Thomas, M. Green, D. P. Lovell, C. Topham, C. Marks, H. Modjtahedi. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients.- Int. J. Oncol., 28, 2006, No 2, 329-335.

Cunningham, M. P., H. Thomas, C. Marks, M. Green, Z. Fan, H. Modjtahedi. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.- Int. J. Oncol., 33, 2008, No 5, 1107-1113.

de Castro-Carpeño, J., C. Belda-Iniesta, E. Casado Sáenz, E. Hernández Agudo, J. Feliu Batlle, M. González Barón. EGFR and colon cancer: a clinical view.- Clin. Transl. Oncol., 10, 2008, No 1, 6-13.

Galizia, G., E. Lieto, F. Ferraraccio, F. De Vita, P. Castellano, M. Orditura, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery.- Ann. Surg. Oncol., 13, 2006, No 6, 823-835.

Giannopoulou, E., A. Antonacopoulou, K. Floratou, A. G. Papavassiliou, H. P. Kalofonos. Dual targeting of EGFR and HER-2 in colon cancer cell lines.- Cancer Chemother. Pharmacol., 63, 2009, No 6, 973-981.

Hadjiolov, N., A. Bitsch, H. G. Neumann. Early initiating and promoting effects in 2-AAF induced rat liver carcinogenesis: an immunohistochemical study.- Cancer Lett., 98, 1995, No 1, 39-46.

Kuwai, T., T. Nakamura, T. Sasaki, Y. Kitadai, J. S. Kim, R. P. Langley, et al. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.- Clin. Exp. Metastasis, 25, 2008, No 4, 477-489.

Resnick, M. B., J. Routhier, T. Konkin, E. Sabo, V. E. Pricolo. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.- Clin. Cancer Res., 10, 2004, No 9, 3069-3075.

Tavolari, S., A. Munarini, G. Storci, S. Laufer, P. Chieco, T. Guarnieri. The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells.- Cancer Lett., 321, 2012, No 2, 187-194.

Vial, D., P. J. McKeown-Longo. Epidermal growth factor (EGF) regulates α5β1integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A.- J. Biol. Chem., 287, 2012, No 48, 40371-40380.

Wang, J., J. Hollingshead, N. El-Masry, D. Horncastle, I. Talbot, I. Tomlinson, M. R. Alison, M. El-Bahrawy. Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.- J. Gastrointest. Cancer, 43, 2012, No 3, 444-455.

Wong, R., D. Cunningham. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.- J. Clin. Oncol., 26, 2008, No 35, 5668-5670.

Xie, G., Z. Peng, J. P. Raufman. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation.- Am. J. Physiol. Gastrointest. Liver Physiol., 302, 2012, No 9, G1006-G1015.

Yantiss, R. K., M. Goodarzi, X. K. Zhou, H. Rennert, E. C. Pirog, B. F. Banner, Y. T. Chen. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.- Am. J. Surg. Pathol., 33, 2009, No 4, 572-582.




DOI: http://dx.doi.org/10.14748/vmf.v2i1.1081

Refbacks

Font Size


|